Calithera Biosciences, Inc. (CALA)
USD 0.01
(4900.0%)
USD 0.01
(4900.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2022 | 136 Thousand USD | -91.84% |
| 2021 | 1.66 Million USD | -65.4% |
| 2020 | 4.81 Million USD | -28.33% |
| 2019 | 6.71 Million USD | 0.0% |
| 2018 | - USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2016 | - USD | 0.0% |
| 2015 | - USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2022 Q2 | 917 Thousand USD | -29.19% |
| 2022 Q1 | 1.29 Million USD | -22.27% |
| 2022 FY | 136 Thousand USD | -91.84% |
| 2022 Q4 | 136 Thousand USD | -74.48% |
| 2022 Q3 | 533 Thousand USD | -41.88% |
| 2021 Q2 | 2.36 Million USD | -12.52% |
| 2021 Q1 | 2.7 Million USD | -43.78% |
| 2021 Q3 | 2.02 Million USD | -14.61% |
| 2021 Q4 | 1.66 Million USD | -17.61% |
| 2021 FY | 1.66 Million USD | -65.4% |
| 2020 Q3 | 5.31 Million USD | -8.29% |
| 2020 FY | 4.81 Million USD | -28.33% |
| 2020 Q4 | 4.81 Million USD | -9.34% |
| 2020 Q1 | 6.26 Million USD | -6.82% |
| 2020 Q2 | 5.79 Million USD | -7.49% |
| 2019 Q4 | 6.71 Million USD | -6.11% |
| 2019 Q1 | 7.98 Million USD | 0.0% |
| 2019 FY | 6.71 Million USD | 0.0% |
| 2019 Q3 | 7.15 Million USD | -5.56% |
| 2019 Q2 | 7.57 Million USD | -5.16% |
| 2018 Q3 | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2018 FY | - USD | 0.0% |
| 2018 Q4 | - USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| America Great Health | 1.12 Million USD | 87.891% |
| Ampio Pharmaceuticals, Inc. | - USD | -Infinity% |
| Aridis Pharmaceuticals, Inc. | 1.29 Million USD | 89.474% |
| Biora Therapeutics, Inc. | 43.73 Million USD | 99.689% |
| Bio-Path Holdings, Inc. | 10 Thousand USD | -1260.0% |
| Better Therapeutics, Inc. | 10.34 Million USD | 98.686% |
| Comera Life Sciences Holdings, Inc. | 120.3 Thousand USD | -13.049% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | - USD | -Infinity% |
| Eloxx Pharmaceuticals, Inc. | 8.69 Million USD | 98.435% |
| Evelo Biosciences, Inc. | 48.87 Million USD | 99.722% |
| Evolutionary Genomics, Inc. | 3.74 Million USD | 96.367% |
| Finch Therapeutics Group, Inc. | 28.4 Million USD | 99.521% |
| Galera Therapeutics, Inc. | 151.04 Million USD | 99.91% |
| Innovation1 Biotech Inc. | 218.99 Thousand USD | 37.899% |
| Kiromic BioPharma, Inc. | 911.5 Thousand USD | 85.08% |
| Molecular Templates, Inc. | 9.74 Million USD | 98.604% |
| Navidea Biopharmaceuticals, Inc. | 1.87 Million USD | 92.734% |
| NexImmune, Inc. | - USD | -Infinity% |
| Orgenesis Inc. | 19.06 Million USD | 99.287% |
| Panbela Therapeutics, Inc. | 4.19 Million USD | 96.757% |
| Point of Care Nano-Technology, Inc. | - USD | -Infinity% |
| PaxMedica, Inc. Common Stock | - USD | -Infinity% |
| Scopus BioPharma Inc. | - USD | -Infinity% |
| Sorrento Therapeutics, Inc. | 104.33 Million USD | 99.87% |
| Statera Biopharma, Inc. | 11.43 Million USD | 98.81% |
| TRACON Pharmaceuticals, Inc. | 732 Thousand USD | 81.421% |
| Trevena, Inc. | 35.23 Million USD | 99.614% |
| Vaxxinity, Inc. | 13.26 Million USD | 98.975% |
| Vaccinex, Inc. | 26 Thousand USD | -423.077% |
| Vicapsys Life Sciences, Inc. | - USD | -Infinity% |
| Viracta Therapeutics, Inc. | - USD | -Infinity% |
| ZIVO Bioscience, Inc. | - USD | -Infinity% |